Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry.

Jatuworapruk K, Montgomery A, Gianfrancesco M, Conway R, Durcan L, Graef ER, Jayatilleke A, Keen H, Kilian A, Young K, Carmona L, Cogo AK, Duarte-García A, Gossec L, Hasseli R, Hyrich KL, Langlois V, Lawson-Tovey S, Malcata A, Mateus EF, Schafer M, Scirè CA, Sigurdardottir V, Sparks JA, Strangfeld A, Xavier RM, Bhana S, Gore-Massy M, Hausmann J, Liew JW, Sirotich E, Sufka P, Wallace Z, Machado PM, Yazdany J, Grainger R, Robinson PC

ACR Open Rheumatol - (-) - [2022-08-24; online 2022-08-24]

To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.

Category: Health

Type: Journal article

PubMed 36000538

DOI 10.1002/acr2.11495

Crossref 10.1002/acr2.11495

Publications 9.5.0